Anaptysbio (ANAB) Gains from Investment Securities (2016 - 2017)
Anaptysbio (ANAB) posted Gains from Investment Securities of $1.4 million for Q1 2017, up 25.21% on a QoQ basis from $1.1 million in Q4 2016, and up 460.42% year-over-year from $243744.8 in Q1 2016.
Anaptysbio (ANAB) Gains from Investment Securities (2016 - 2017) Analysis & Trends
Anaptysbio's Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $1.4 million for Q1 2017.
- Quarterly Gains from Investment Securities rose 460.42% year-over-year to $1.4 million in Q1 2017, while the trailing twelve-month figure through Dec 2017 was $1.4 million (up 80.69% YoY) and the FY2017 annual result came in at $1.4 million, up 80.69% from the prior year.
- Gains from Investment Securities was $1.4 million for Q1 2017 at Anaptysbio, up from $1.1 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $1.4 million in Q1 2017 and bottomed at -$379000.0 in Q1 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn |
| 10 | Anaptysbio | 1.56 Bn | 1.28 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 1.37 Mn |
| Mar 31, 2017 | 1.37 Mn |
| Dec 31, 2016 | 1.09 Mn |
| Dec 31, 2016 | 1.09 Mn |
| Sep 30, 2016 | 47,000.00 |
| Sep 30, 2016 | 47,000.00 |
| Jun 30, 2016 | -3,000.00 |
| Jun 30, 2016 | -3,000.00 |
| Mar 31, 2016 | -379,000.00 |
| Mar 31, 2016 | -379,000.00 |